USP8 and intrahepatic cholangiocarcinoma: Furthermore, it has been reported that targeting USP8 with DUB-IN-3, a specific inhibitor of USP8, could suppress the progression of HCC and intrahepatic cholangiocarcinoma (iCCA) [47, 50].